Related Experiment Video
Updated: Dec 14, 2025

The Use of a β-lactamase-based Conductimetric Biosensor Assay to Detect Biomolecular Interactions
Published on: February 1, 2018
Metallo-β-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline
Sara E Boyd1,2, David M Livermore3, David C Hooper4
1Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom s.e.boyd@liverpool.ac.uk.
Antibiotic resistance from Gram-negative bacteria is a growing threat. Metallo-β-lactamases (MBLs) are concerning, but may be less effective in vivo, offering hope for new drug development.
Area of Science:
- Microbiology
- Infectious Diseases
- Drug Discovery
Background:
- Global rise of antibiotic resistance, particularly in Gram-negative bacteria.
- Metallo-β-lactamases (MBLs) are a significant concern, with increasing worldwide dissemination, especially in Asia.
- MBL-producing bacteria often exhibit multidrug resistance, limiting treatment options.
Purpose of the Study:
- To review the challenge posed by Metallo-β-lactamases (MBLs) in antibiotic resistance.
- To discuss the development pipeline for new therapies targeting MBLs.
- To examine the epidemiology of MBL producers and current treatment strategies.
Main Methods:
- Literature review of scientific publications on MBLs and antibiotic resistance.
- Analysis of MBL enzyme structure, function, and diversity.
- Evaluation of current and developing therapeutic strategies, including beta-lactam/inhibitor combinations.
Main Results:
- Metallo-β-lactamases (MBLs) present a unique challenge for drug development due to their structure and diversity.
- MBLs evade currently licensed beta-lactam/inhibitor combinations.
- MBLs may be less effective in vivo under zinc limitation compared to in vitro.
- Several novel agents and inhibitor combinations are in development.
Conclusions:
- The unique characteristics of MBLs necessitate innovative approaches for effective treatment.
- Ongoing research and development offer promising new therapeutic avenues.
- Understanding MBL epidemiology is crucial for guiding treatment and control strategies.
Related Concept Videos
Development of Antibiotic Resistance
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Acute Pyelonephritis II: Diagnostic Studies and Management
Biological Methods for Microbial Control
Biofilms

